About Us

Royal Philips, a global leader in health technology, is expanding its cardiac diagnostics and monitoring portfolio with the strategic acquisition of Cardiology, a France-based medtech company specializing in artificial intelligence (AI) and cloud technology for cardiac diagnostics. Cardiology enhances Philips' existing cardiac care solutions by adding innovative software technology, electrocardiogram (ECG) analysis, and reporting services designed to accelerate diagnostic reporting, reduce errors, and streamline clinician workflow. Cardiologist vendor-neutral technology, including a heart disorder screener and ECG analysis applications, is CE-marked and FDA-cleared for detecting cardiac arrhythmias. It is supported by a database of over 20 million ECG recordings and numerous clinical publications. This acquisition will allow Philips to offer improved patient care experiences, better health outcomes, and lower care costs, in line with the company's commitment to the quadruple aim in healthcare. The acquisition is expected to further Philips' mission to improve people's health and well-being by integrating Cardiologs' medical-grade AI technology and data scientists into its growing portfolio of cardiac solutions for both hospital and ambulatory settings. The Cardiology team is primarily composed of software engineers and data scientists with expertise in AI.